See more : InBankshares, Corp (INBC) Income Statement Analysis – Financial Results
Complete financial analysis of Cellectis S.A. (CLLS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Cellectis S.A., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Model Performance Acquisition Corp. (MPAC) Income Statement Analysis – Financial Results
- Beijing Airdoc Technology Co., Ltd. (2251.HK) Income Statement Analysis – Financial Results
- Hextar Healthcare Berhad (7803.KL) Income Statement Analysis – Financial Results
- Pujiang International Group Limited (2060.HK) Income Statement Analysis – Financial Results
- MTN Group Limited (MTN.JO) Income Statement Analysis – Financial Results
Cellectis S.A. (CLLS)
About Cellectis S.A.
Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma; ALLO-316 for the treatment of Renal Cell Carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART22 to treat B-cell acute lymphoblastic leukemia. It is also developing UCARTCS1 and ALLO-715 for the treatment of multiple myeloma. The company has strategic alliances with Allogene Therapeutics, Inc.; Les Laboratoires Servier; The University of Texas M.D. Anderson Cancer Center; and Iovance Biotherapeutics, as well as a strategic research and development collaboration with Cytovia Therapeutics, Inc. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 755.00K | 19.17M | 73.95M | 73.95M | 15.19M | 12.73M | 25.19M | 42.58M | 55.04M | 26.30M | 22.82M | 27.81M | 20.73M | 20.98M | 17.32M | 14.77M | 4.10M |
| Cost of Revenue | 737.00K | 1.77M | 36.28M | 36.28M | 11.39M | 2.74M | 2.62M | 1.69M | 2.71M | 3.69M | 847.86K | 2.03M | 3.26M | 1.92M | 2.33M | 1.54M | 1.48M |
| Gross Profit | 18.00K | 17.40M | 37.67M | 37.67M | 3.80M | 9.99M | 22.57M | 40.90M | 52.34M | 22.61M | 21.97M | 25.78M | 17.47M | 19.06M | 14.99M | 13.23M | 2.62M |
| Gross Profit Ratio | 2.38% | 90.76% | 50.95% | 50.95% | 25.00% | 78.49% | 89.60% | 96.04% | 95.08% | 85.97% | 96.28% | 92.70% | 84.27% | 90.84% | 86.57% | 89.56% | 63.99% |
| Research & Development | 87.65M | 97.50M | 86.95M | 86.95M | 92.04M | 76.57M | 79.23M | 74.56M | 57.30M | 17.52M | 34.44M | 25.10M | 15.95M | 16.37M | 0.00 | 0.00 | 0.00 |
| General & Administrative | 16.81M | 17.49M | 37.87M | 44.20M | 43.02M | 47.25M | 44.75M | 41.26M | 29.78M | 15.95M | 30.49M | 0.00 | 0.00 | 0.00 | 7.97M | 5.70M | 4.28M |
| Selling & Marketing | 0.00 | 3.11M | 6.33M | 1.66M | 11.43M | 16.69M | 9.14M | 8.41M | 6.67M | 6.57M | 18.14M | 0.00 | 0.00 | 17.90M | 0.00 | 0.00 | 0.00 |
| SG&A | 16.81M | 17.49M | 44.20M | 44.20M | 43.02M | 47.25M | 44.75M | 41.26M | 29.78M | 15.95M | 30.49M | 25.83M | 26.69M | 17.90M | 7.97M | 5.70M | 4.28M |
| Other Expenses | -7.14M | -7.93M | -8.04M | -8.04M | -7.71M | -25.42M | -17.90M | -19.38M | -10.88M | -11.05M | -15.95M | 995.85K | 142.57K | 35.91K | 19.54M | 12.32M | 4.37K |
| Operating Expenses | 97.32M | 107.07M | 123.11M | 123.11M | 127.35M | 115.08M | 115.22M | 104.86M | 82.87M | 28.98M | 67.13M | 51.92M | 42.78M | 34.31M | 27.51M | 18.03M | 10.41M |
| Cost & Expenses | 98.06M | 108.84M | 159.39M | 159.39M | 138.74M | 117.82M | 117.84M | 106.54M | 85.57M | 32.68M | 67.97M | 53.95M | 46.04M | 36.23M | 29.84M | 19.57M | 11.88M |
| Interest Income | 3.61M | 1.12M | 736.00K | 1.95M | 8.34M | 16.76M | 1.97M | 44.17K | 8.25M | 384.26K | 437.74K | 477.82K | 794.50K | 645.03K | 1.79M | 1.13M | 835.44K |
| Interest Expense | 6.43M | 3.79M | 5.34M | 12.05M | 2.61M | 46.00K | 4.00K | 6.31K | 22.96K | 195.78K | 407.36K | 2.32M | 632.49K | 203.48K | 8.60K | 13.92K | 29.16K |
| Depreciation & Amortization | 18.52M | 18.44M | 14.16M | 9.82M | 6.88M | 2.38M | 3.37M | 2.21M | 1.91M | 1.67M | 45.93M | 2.42M | 804.87K | 1.58M | 368.22K | 400.92K | 852.93K |
| EBITDA | -92.64M | -76.38M | -86.46M | -34.68M | -105.09M | -93.79M | -108.08M | -65.32M | -26.21M | 370.08K | 1.17M | -26.14M | -25.31M | -12.98M | -12.25M | -3.36M | -5.99M |
| EBITDA Ratio | -12,269.67% | -467.72% | -115.54% | -115.54% | -813.38% | -825.47% | -367.83% | -150.20% | -52.00% | -16.86% | 5.13% | -93.98% | -118.21% | -61.87% | -59.13% | -21.56% | -148.45% |
| Operating Income | -106.63M | -89.67M | -85.44M | -85.44M | -123.55M | -105.09M | -92.65M | -63.96M | -30.53M | -6.38M | -80.62M | -26.14M | -25.31M | -15.25M | -13.50M | -4.80M | -7.78M |
| Operating Income Ratio | -14,122.65% | -467.72% | -115.54% | -115.54% | -813.38% | -825.47% | -367.83% | -150.20% | -55.46% | -24.25% | -353.35% | -93.98% | -122.09% | -72.68% | -77.92% | -32.48% | -189.73% |
| Total Other Income/Expenses | -16.42M | -8.94M | 6.73M | -12.05M | 8.34M | 16.76M | -11.03M | 47.00K | 8.38M | 8.63M | -3.99M | -1.90M | 172.38K | 486.77K | 812.28K | 1.10M | 810.65K |
| Income Before Tax | -123.05M | -98.60M | -97.48M | -97.48M | -115.21M | -88.33M | -103.68M | -63.92M | -22.27M | 2.25M | -81.09M | -27.87M | -25.14M | -14.76M | -11.72M | -3.68M | -6.97M |
| Income Before Tax Ratio | -16,297.48% | -514.32% | -131.82% | -131.82% | -758.47% | -693.84% | -411.63% | -150.09% | -40.47% | 8.56% | -355.39% | -100.21% | -121.26% | -70.36% | -67.66% | -24.94% | -169.96% |
| Income Tax Expense | -6.21M | 87.00K | -11.20M | -24.91M | -24.53M | 16.81M | -13.20M | -1.54M | -926.03K | 2.42M | 4.68M | 1.58M | 5.76M | -4.04M | -6.20M | -3.87M | -2.61M |
| Net Income | -101.06M | -98.69M | -86.28M | -72.57M | -90.69M | -78.69M | -99.37M | -63.92M | -22.46M | 24.32K | -84.28M | -29.45M | -30.90M | -10.72M | -5.52M | 185.15K | -4.36M |
| Net Income Ratio | -13,385.30% | -514.78% | -116.68% | -98.14% | -597.01% | -618.12% | -394.51% | -150.10% | -40.81% | 0.09% | -369.38% | -105.89% | -149.05% | -51.11% | -31.87% | 1.25% | -106.22% |
| EPS | -1.77 | -2.17 | -1.93 | -1.71 | -2.14 | -1.93 | -2.78 | -1.81 | -0.66 | 0.00 | -4.08 | -1.48 | -2.19 | -0.76 | -0.39 | 0.01 | -0.31 |
| EPS Diluted | -1.77 | -2.17 | -1.93 | -1.71 | -2.14 | -1.93 | -2.78 | -1.78 | -0.65 | 0.00 | -4.08 | -1.48 | -2.19 | -0.76 | -0.39 | 0.01 | -0.31 |
| Weighted Avg Shares Out | 57.01M | 45.55M | 44.82M | 42.50M | 42.44M | 40.77M | 35.69M | 35.29M | 34.15M | 26.07M | 20.65M | 19.94M | 14.13M | 14.13M | 14.13M | 14.13M | 14.13M |
| Weighted Avg Shares Out (Dil) | 57.01M | 45.55M | 44.82M | 42.50M | 42.44M | 40.77M | 35.69M | 35.81M | 34.52M | 26.19M | 20.65M | 19.94M | 14.13M | 14.13M | 14.13M | 14.13M | 14.13M |
Cellectis' Annual Shareholders' General Meeting to be Held on June 1, 2021
NEW YORK, April 26, 2021 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS).
Monthly information on share capital and company voting rights
(Article 223-16 of General Regulation of the French financial markets authority)
Cellectis Completes Sale of $47 million through its ATM program
NEW YORK, April 09, 2021 (GLOBE NEWSWIRE) -- Cellectis S.A. (NASDAQ: CLLS – EURONEXT GROWTH: ALCLS) (the “Company”), a clinical-stage biotechnological company employing its core proprietary technologies to develop best-in-class products based on gene-edited allogeneic CAR T-cells in the field...
Cellectis Establishes an At-The-Market (ATM) Program on Nasdaq
NEW YORK, March 29, 2021 (GLOBE NEWSWIRE) -- Cellectis S.A. (NASDAQ: CLLS – EURONEXT GROWTH: ALCLS) (the “Company”), a clinical-stage biotechnological company employing its core proprietary technologies to develop best-in-class products based on gene-edited allogeneic CAR T-cells in the field...
Monthly information on share capital and company voting rights
(Article 223-16 of General Regulation of the French financial markets authority)
Cellectis S.A. (CLLS) CEO André Choulika on Q4 2020 Results - Earnings Call Transcript
Cellectis S.A. (CLLS) CEO André Choulika on Q4 2020 Results - Earnings Call Transcript
Cellectis: Q4 Earnings Insights
Shares of Cellectis (NASDAQ:CLLS) were flatin after-market trading after the company reported Q4 results. Quarterly Results Earnings per share fell 20.55% year over year to ($0.88), which missed the estimate of ($0.78).
Cellectis Provides Business Update and Reports 4th Quarter and Full Year 2020 Financial Results
NEW YORK, March 04, 2021 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on allogeneic gene-edited CAR T-cells (UCART), today announced its results for the fourth quarter of 2020, and...
Cellectis to Hold Fourth Quarter 2020 Earnings Call on Friday, March 5, 2021 at 8:00AM EST
NEW YORK, Feb. 25, 2021 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic CAR T-cells (UCART), announced that it will report its financial results for the fourth quarter...
Cellectis, Cytovia Therapeutics Ink Gene-Edited Therapy Pact For Oncology Indications
Cytovia Therapeutics Inc and Cellectis SA (NASDAQ: CLLS) have entered into a strategic research and development collaboration to develop TALEN gene-edited induced pluripotent stem cells (iPSC) Natural Killer (NK) and Chimeric Antigen Receptor (CAR)-NK cells. Cellectis will receive up to $760 million in milestone payments from...
Source: https://incomestatements.info
Category: Stock Reports